Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.

BACKGROUND Introduction of human papillomavirus (HPV) vaccination in settings with the highest burden of HPV is not universal, partly because of the absence of quantitative estimates of country-specific effects on health and economic costs. We aimed to develop and validate a simple generic model of such effects that could be used and understood in a range of settings with little external support. METHODS We developed the Papillomavirus Rapid Interface for Modelling and Economics (PRIME) model to assess cost-effectiveness and health effects of vaccination of girls against HPV before sexual debut in terms of burden of cervical cancer and mortality. PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine protection and no changes to other screening programmes or vaccine uptake. We validated PRIME against existing reports of HPV vaccination cost-effectiveness, projected outcomes for 179 countries (assuming full vaccination of 12-year-old girls), and outcomes for 71 phase 2 GAVI-eligible countries (using vaccine uptake data from the GAVI Alliance). We assessed differences between countries in terms of cost-effectiveness and health effects. FINDINGS In validation, PRIME reproduced cost-effectiveness conclusions for 24 of 26 countries from 17 published studies, and for all 72 countries in a published study of GAVI-eligible countries. Vaccination of a cohort of 58 million 12-year-old girls in 179 countries prevented 690,000 cases of cervical cancer and 420,000 deaths during their lifetime (mostly in low-income or middle-income countries), at a net cost of US$4 billion. HPV vaccination was very cost effective (with every disability-adjusted life-year averted costing less than the gross domestic product per head) in 156 (87%) of 179 countries. Introduction of the vaccine in countries without national HPV vaccination at present would prevent substantially more cases of cervical cancer than in countries with such programmes, although the disparity has narrowed since 2012. If 71 phase 2 GAVI-eligible countries adopt vaccination according to forecasts, then in 2070 GAVI Alliance-funded vaccination could prevent 200,000 cases of cervical cancer and 100,000 deaths in some of the highest-burden countries. INTERPRETATION Large between-country disparities exist for HPV vaccination, with countries with the most to gain yet to introduce national HPV vaccination. Support from the GAVI Alliance could help to reduce such disparities, but a substantial burden will remain even after presently projected vaccine introductions. FUNDING WHO.

[1]  X. Castellsagué,et al.  Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths. , 2014, Vaccine.

[2]  M. Robson,et al.  A Model for Enhancing Evidence-Based Capacity to Make Informed Policy Decisions on the Introduction of New Vaccines in the Americas: Paho's Provac Initiative , 2007, Public health reports.

[3]  N. Broutet Comprehensive Cervical Cancer Control: Strategies and Guidelines , 2013 .

[4]  T. Edejer,et al.  Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis. , 2009, Vaccine.

[5]  M. Boily,et al.  Economic Evaluation of Human Papillomavirus Vaccination in Developed Countries , 2009, Public Health Genomics.

[6]  C. Marra,et al.  The Cost Effectiveness of Human Papillomavirus Vaccines , 2012, Drugs.

[7]  H. Cubie,et al.  Human papillomavirus vaccine introduction--the first five years. , 2012, Vaccine.

[8]  S. Goldie,et al.  Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. , 2008, Vaccine.

[9]  M. Jit,et al.  Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. , 2013, Vaccine.

[10]  M. Seoud,et al.  Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA). , 2013, Vaccine.

[11]  J. Berkhof,et al.  Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia. , 2013, Vaccine.

[12]  P. Lopalco,et al.  The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[13]  D. Koleva,et al.  Economic evaluation of human papilloma virus vaccination in the European Union: a critical review , 2011, Internal and emergency medicine.

[14]  P. Maisonneuve,et al.  Carcinoma of the cervix uteri , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[15]  J. Berkhof,et al.  Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts , 2013, BMC Medicine.

[16]  S. Garland,et al.  Human Papillomavirus Vaccines , 2010, Drugs.

[17]  Who,et al.  Human papillomavirus vaccines: WHO position paper. , 2009, Biologicals : journal of the International Association of Biological Standardization.

[18]  Alan D. Lopez,et al.  Global burden of disease and risk factors , 2006 .

[19]  A. Rothberg Making Choices in Health: WHO Guide to Cost Effectiveness Analysis , 2008 .

[20]  P. Maisonneuve,et al.  Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. , 2006, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[21]  Alan D. Lopez,et al.  The Burden of Disease and Mortality by Condition: Data, Methods, and Results for 2001 -- Global Burden of Disease and Risk Factors , 2006 .

[22]  S. Franceschi,et al.  Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication , 2011, International journal of cancer.

[23]  P. Bonanni,et al.  Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. , 2009, Vaccine.

[24]  C. Marra,et al.  Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine , 2012, PharmacoEconomics.

[25]  Rob Baltussen,et al.  Making Choices in Health: WHO Guide to Cost Effectiveness Analysis , 2003 .

[26]  H. Cubie,et al.  Corrigendum to: “Human Papillomavirus Vaccine Introduction – The First Five Years” [Vaccine 30 (Suppl. 5) (2012) F139–F148] , 2014 .

[27]  Jacques Ferlay,et al.  GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 , 2013 .

[28]  Jane J. Kim,et al.  Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa. , 2013, Vaccine.

[29]  Marc Brisson,et al.  Modeling cervical cancer prevention in developed countries. , 2008, Vaccine.